biote Corp. Stock

Equities

BTMD

US0906831039

Professional Information Services

Market Closed - Nasdaq 04:00:00 2024-05-28 pm EDT 5-day change 1st Jan Change
6.59 USD +3.78% Intraday chart for biote Corp. +16.84% +33.40%
Sales 2024 * 202M Sales 2025 * 233M Capitalization 182M
Net income 2024 * 12M Net income 2025 * 27M EV / Sales 2024 * 1.13 x
Net Debt 2024 * 45M Net Debt 2025 * 22.45M EV / Sales 2025 * 0.88 x
P/E ratio 2024 *
28.7 x
P/E ratio 2025 *
12.7 x
Employees 194
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.78%
1 week+16.84%
Current month+19.60%
1 month+19.38%
3 months+5.44%
6 months+29.22%
Current year+33.40%
More quotes
1 week
5.57
Extreme 5.57
6.72
1 month
5.15
Extreme 5.15
6.72
Current year
3.65
Extreme 3.6538
7.50
1 year
3.65
Extreme 3.6538
8.22
3 years
2.00
Extreme 2
10.53
5 years
2.00
Extreme 2
10.53
10 years
2.00
Extreme 2
10.53
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 22-04-30
Director of Finance/CFO 47 Jan. 07
Chief Tech/Sci/R&D Officer 62 19-05-31
Members of the board TitleAgeSince
Director/Board Member 71 22-04-30
Director/Board Member 66 22-04-30
Chairman 59 22-04-30
More insiders
Date Price Change Volume
24-05-28 6.59 +3.78% 259,445
24-05-24 6.35 +7.63% 202,120
24-05-23 5.9 +1.20% 147,642
24-05-22 5.83 +4.67% 59,492
24-05-21 5.57 -1.24% 122,667

Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT

More quotes
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
6.35 USD
Average target price
8.866 USD
Spread / Average Target
+39.62%
Consensus